Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 12/20 | 0.51 |
| ▸ | BRAF | P15056 | 4/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442522 | 0.96 | NTRK1 (0.58) | NTRK1KDRBRAFABL1HTR2A | |
| SCHEMBL5441833 | 0.92 | ABL1 (0.55) | NTRK1BRAFABL1AURKBCSF1R | |
| SCHEMBL5457893 | 0.91 | NTRK1 (0.63) | NTRK1KDRBRAFABL1RET | |
| SCHEMBL5452721 | 0.88 | NTRK1 (0.72) | NTRK1KDRBRAFABL1RET | |
| SCHEMBL5338760 | 0.87 | NTRK1 (0.66) | NTRK1KDRBRAFABL1RET | |
| SCHEMBL5345816 | 0.87 | KDR (0.65) | NTRK1KDRBRAFABL1RET | |
| SCHEMBL5431936 | 0.86 | KDR (0.66) | NTRK1KDRBRAFRET | |
| SCHEMBL5333938 | 0.83 | KDR (0.54) | NTRK1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL5429189 | 0.82 | KDR (0.73) | NTRK1KDRBRAFABL1HTR2A | |
| SCHEMBL5447211 | 0.82 | NTRK1 (0.60) | NTRK1KDRBRAFABL1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | NTRK1 578/4885KDR 555/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.